A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The study will evaluate the safety, tolerability, and immunogenicity (your immune system\'s reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
Epistemonikos ID: 0aa5c0152bbaf1787cd305c4fd6cf20e6aab179d
First added on: May 15, 2024